Two types of vaccines were used for the study: one constructed with genetically engineered DNA molecules that teach immune system cells to recognize premalignant cells expressing HPV16 E7 proteins, and one that is a non-infectious, engineered virus that targets and kills
precancerous cells marked by HPV16 and HPV18 E6 and E7 proteins.